I don't think that many knowledgeable investors are "expecting" an OS advantage for C/Z over T/D. Most expect reasonably "in the same ballpark" OS results, meaning several months one way or the other. Both of these combos will have a place in the treatment sequence in all likelihood, so an approval is still a good thing for EXEL.
What you do with your shares is obviously no one's business, but traditionally you have switched sentiments back and forth on a daily, or intra-daily basis. You may very well be laughing at me in the near future, but I am just stupid enough to continue holding, with an eye toward RCC approval for Cabo. Cobi is a sideshow, albeit a potentially worthwhile sideshow, but the big show is still Cabozantinib.